vTv Therapeutics Inc (NASDAQ:VTVT) watched its shares move skyward Friday, after the company announced the results of a multiple ascending dose study evaluating HPP737 in healthy adults.
HPP737 is an orally administered phosphodiesterase type 4 (PDE4) inhibitor. The 12-subject trial had two dose cohorts, 15mg and 20mg.
Dose escalation up to 20mg/day demonstrated approximate dose-proportional increases in exposure.
The drug candidate maintained a favorable safety and tolerability profile with no dose-limiting safety or tolerability, particularly with no dose-limiting gastrointestinal adverse events.
There were no serious adverse events and no discontinuations due to treatment-emergent adverse events.
vTv is of the opinion that HPP737 can be developed further for anti-inflammatory and anti-psoriatic responses.
The two multiple ascending dose studies will be presented at an upcoming scientific conference focused on dermatology.
Said CEO Steve Holcombe, “We are pleased that the study accomplished its objectives by confirming the anticipated favorable safety and tolerability profile of HPP737, particularly the absence of dose limiting gastrointestinal adverse events, at substantially higher concentrations than previously tested”.
The Company plans to file an IND application later in 2021 for a 12-week Phase 2 trial of HPP737 in moderate to severe psoriasis. The study is targeted to start in early 2022.
Additionally, Newsoara Biopharma, vTv's partner in Asia, is currently conducting Phase 2 studies in chronic obstructive pulmonary disease, psoriasis, and atopic dermatitis in China.
VTVT stock is up 28 cents, or 15.8%, at $2.05 early Friday.
